

7:55 AM	Welcome & Introduction <i>Ron Waksman, MD</i>	9:10 AM	Panel Discussion: What Should the Ideal Carrier/Polymer for DES Be? <i>Moderators: R. S. Schwartz, R. Virmani</i> <i>Panelists: J. F. Granada, J. E. Shulze, A. C. Yeung</i>
Session I <i>Moderators: Robert S. Schwartz, MD and Renu Virmani, MD</i>			
8:00 AM	Histopathologic Insights into DES Thrombosis Can We Design a "Safe" DES? <i>Renu Virmani, MD</i>		Industry Update New DES Programs <i>Moderators: Juan F. Granada, MD and David E. Kandzari, MD</i>
8:10 AM	Multi-Laminate Supercritical Fluid Based Coating Process with Fast-Absorbing Polymer and Crystalline Drug Provides Safe Delivery of Sirolimus in Porcine Coronary Arteries <i>David E. Kandzari, MD</i>	9:15 AM	The NEVO Program: Reservoir-Based Sirolimus-Eluting Stent <i>Sidney A. Cohen, MD, PhD</i>
8:20 AM	OCT for the Longitudinal Evaluation of Vascular Healing Following DES Implantation <i>Juan F. Granada, MD</i>	9:25 AM	The RESOLUTE Program Update <i>Josiah N. Wilcox, PhD</i>
8:30 AM	Coronary Endothelial Dysfunction After DES: Presumed Mechanisms, Assessment Techniques. Are Next Generation DES Associated with Restored Coronary Vasomotion? <i>Alan C. Yeung, MD</i>	9:35 AM	DES Development for the SFA: The Abbott Program <i>Lewis B. Schwartz, MD</i>
8:40 AM	How to Design a Successful Bioabsorbable Polymer Program <i>John E. Shulze</i>	9:45 AM	The XIENCE Program Update <i>Charles A. Simonton, MD</i>
8:50 AM	Emerging Drugs and Polymers: Lessons from First in Man Studies <i>Alexandre Abizaid, MD, PhD</i>	9:55 AM	The BSC Next Generation DES Program Update <i>Keith Dawkins, MD</i>
9:00 AM	A Lesson of Vascular Biocompatibility: Biodegradable Polymer Coating - Titrating Polymer and Drug <i>Refat Jebara, MD</i>	10:05 AM	The MIV Hydroxyapatite-Coated Polymer-Free DES System: Design Concept and Experimental Studies <i>Alexandre Abizaid, MD, PhD</i>
		10:15 AM	Medtronic CardioVascular Combination Development Pipeline <i>Josiah N. Wilcox, PhD</i>
		10:25 AM	Abluminal Microstructure DES Coating Technology <i>Arthur L. Rosenthal, PhD</i>
		10:35 AM	The BIOFREEDOM Surface Etching Polymer-Free DES System <i>John E. Shulze</i>

10:45 AM The Novolimus-Eluting Durable Polymer Stent FIM Study: One Year
Alexandre Abizaid, MD, PhD

10:55 AM What would it Take to Prove Reduction of Late Stent Thrombosis with Second Generation DES?
Laura Mauri, MD

11:05 AM Break

Bioabsorbable Stent Symposium

Moderators: Andrew Farb, MD and Harry R. Phillips, MD

11:20 AM The BTI Salicylate-Based Polyanhydride Ester Absorbable Sirolimus- Eluting Stent
Maurice Buchbinder, MD

11:30 AM Update on the Development and Clinical Trials of Absorbable Magnesium Stents
Ron Waksman, MD

11:40 AM Bioabsorbable Vascular Solutions: The ABSORB Trial
Richard J. Rapoza, PhD

11:50 AM The Reva Bioabsorbable Stent Program
Eberhard Grube, MD

12:00 PM Regulatory Challenges for Biodegradable Stent Approval
Andrew Farb, MD

12:10 PM Panel Discussion: The Future of the Biodegradable Stent
Moderator: J. J. Popma
Panelists: A. B. Boam, A. Farb, E. Grube, R. Jabara, R. J. Rapoza, R. Virmani, R. Waksman

12:25 PM Xtent Technology: Programmable Length Drug Eluting Stents
Eberhard Grube, MD

12:35 PM Lunch & Visit the Exhibits

DES Challenges

Moderators: Donald E. Cutlip, MD and Laura Mauri, MD

1:35 PM How Did the SYNTAX Study Change My Practice?
Harry R. Phillips, MD

1:45 PM The Strength and the Limitations of the Arc Definition: Will it be Updated?
Donald E. Cutlip, MD

1:55 PM Should Patients Undergoing DES Implantation Routinely Test Their Responsiveness to Aspirin and Clopidogrel?
Paul A. Gurbel, MD

2:05 PM Stent Fracture: The Magnitude of the Problem
Jeffrey J. Popma, MD

2:15 PM Are Drug Eluting Stents Safe? A Candid Analysis of the Data
Jeff A. Brinker, MD

2:25 PM Is Prolonged Dual Antiplatelet Therapy the Remedy for Late Stent Thrombosis?
Laura Mauri, MD

2:35 PM Should the FDA Ease the Requirements for New DES Programs?
Ashley B. Boam, MSBE

2:45 PM Break

Expanding the Indications for DES

Moderators: Bernard Chevalier, MD and Jeffrey J. Popma, MD

3:00 PM Broad use of DES: The European Experience
Bernard R. Chevalier, MD

3:10 PM DES for Unprotected LM
Adnan Kastrati, MD

3:20 PM DES for Acute MI: Are We Ready to Expand the Indication?
Martin B. Leon, MD

Thursday, March 5, 2009

3:30 PM	DES for the Diabetic Patient <i>Keith Dawkins, MD</i>	Alternatives to Drug Eluting Stent Technology <i>Moderators: Alexandre Abizaid, MD, PhD and Ron Waksman, MD</i>
3:40 PM	DES for In-Stent Restenosis <i>Ron Waksman, MD</i>	4:30 PM The BRAUN Paclitaxel-Eluting Balloon Program: Experimental Findings, and Clinical Outcomes in Patients with In-Stent Restenosis and for Small Vessels, SFA (The PEPCAD trials) <i>Bodo Cremers, MD</i>
3:50 PM	How to Choose a DES: TAXUS, CYPHER, XIENCE, Endeavor? <i>Jeffrey J. Popma, MD</i>	4:40 PM The Catania™ Stent: A New Class of Bare Metal Stent <i>Francesco Prati, MD</i>
4:00 PM	Should We Expand DES Indications Based on the Existing Data? <i>Spencer B. King, III, MD</i>	4:50 PM Regulatory Requirements for Drug Eluting Balloons <i>Andrew Farb, MD</i>
4:10 PM	Dedicated Bifurcated DES Programs <i>Alan C. Yeung, MD</i>	5:00 PM Panel Discussion: Will Drug Eluting Balloons Play a Role in Interventional Cardiology and If So to Which Application? <i>Moderators: M. B. Leon, R. Waksman</i> <i>Panelists: B. R. Chevalier, B. Cremers, A. Farb, J. J. Popma, R. Virmani</i>
4:20 PM	Progenitor Cells: HEALING II and III <i>Michael J. Kutryk, MD, PhD</i>	5:30 PM Adjourn